首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1566159

癌症药物市场规模、份额、成长分析、按药物类别、按疗法、按适应症、按剂型、按地区 - 产业预测，2024-2031 年

Oncology Drugs Market Size, Share, Growth Analysis, By Drug Class, By Therapy, By Indication, By Dosage Form, By Region - Industry Forecast 2024-2031

出版日期: 2024年10月05日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球抗癌药物市场规模为1,190亿美元，从2023年的1,336.4亿美元成长到2031年的3,380.4亿美元，预计在预测期内（2024-2031年）成长。 %。

全球抗癌药物市场是製药业快速发展的重要组成部分。癌症药物通常称为抗癌药物或化疗药物，是专门为诊断、治疗和管理各种癌症而开发的。这些药物对于对抗癌症至关重要，因为它们针对癌细胞并抑制其生长或完全消除它们。由于多种因素，该市场正在经历显着成长。受老化、不健康生活方式、环境暴露和遗传倾向等因素影响，全球癌症发生率不断上升，推动了对有效治疗的需求。此外，医学研究和技术的进步促进了创新癌症治疗方法的发展。研究人员和製药公司正在不断探索新的治疗方法，包括标靶治疗、免疫疗法和个人化医疗，有望改善患者的治疗结果和存活率。癌症治疗药物市场多种多样，针对各种癌症类型的药物种类繁多，包括肺癌、乳腺癌、结直肠癌和前列腺癌，有口服、注射和静脉注射形式出售。该领域竞争激烈，各大製药公司在研究、临床试验、监管核准和行销方面投入巨资，以将新产品推向市场。总体而言，在对抗癌症和改善患者治疗效果的持续需求的推动下，癌症治疗市场对于製药业来说是一个充满活力且至关重要的领域。持续的投资、研究和合作对于应对癌症不断变化的挑战和满足世界对有效治疗方法的需求至关重要。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

F. Hoffmann-La Roche Ltd.（Switzerland）
Amgen（US）
Novartis AG（Switzerland）
Bristol-Myers Squibb Company（US）
Pfizer Inc.（US）
Astellas Pharma Inc.（Japan）
Johnson & Johnson（US）
AstraZeneca plc（UK）
AbbVie Inc.（US）
Merck & Co., Inc.（US）
Eli Lilly and Company（US）
Sanofi SA（France）
Gilead Sciences, Inc.（US）
Regeneron Pharmaceuticals, Inc.（US）
Incyte Corporation（US）
Vertex Pharmaceuticals Incorporated（US）
Seagen Inc.（US）
Blueprint Medicines Corporation（US）
Mirati Therapeutics, Inc.（US）
Xencor, Inc.（US）
NantKwest, Inc.（US）
Zymeworks Inc.（Canada）
Karyopharm Therapeutics Inc.（US）
Exelixis, Inc.（US）

简介目录

Product Code: SQMIG35J2087

Global Oncology Drugs Market size was valued at USD 119 billion in 2022 and is poised to grow from USD 133.64 billion in 2023 to USD 338.04 billion by 2031, growing at a CAGR of 12.3% during the forecast period (2024-2031).

The global oncology drug market is a rapidly advancing and crucial segment of the pharmaceutical industry. Oncology drugs, commonly referred to as anticancer or chemotherapy drugs, are specifically developed to diagnose, treat, and manage various types of cancer. These medications are essential in the fight against cancer, as they target and inhibit the growth of cancer cells or eliminate them entirely. The market has experienced significant growth due to several contributing factors. The rising incidence of cancer globally has driven up the demand for effective treatments, influenced by factors such as an aging population, unhealthy lifestyles, environmental exposures, and genetic predispositions. Additionally, advancements in medical research and technology have led to the development of innovative oncology therapies. Researchers and pharmaceutical companies are continuously exploring new treatment options, including targeted therapies, immunotherapies, and personalized medicine, which have demonstrated promising improvements in patient outcomes and survival rates. The oncology drug market is diverse, with a broad range of medications aimed at different cancer types, such as lung, breast, colorectal, and prostate cancers, available in forms like oral pills, injectables, and intravenous infusions. This sector is highly competitive, with major pharmaceutical companies investing heavily in research, clinical trials, regulatory approvals, and marketing to bring new products to market. Overall, the oncology drug market is a dynamic and essential area of the pharmaceutical industry, driven by the ongoing need to combat cancer and enhance patient outcomes. Continued investment, research, and collaboration are vital to addressing the evolving challenges of cancer and meeting the global demand for effective treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oncology Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oncology Drugs Market Segmental Analysis

Global Oncology Drugs Market is segmented by Drug Class, Therapy, Indication, Dosage Form, Distribution Channel, and Region. Based on Drug Class, the market is segmented into Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, Others. Based on Therapy, the market is segmented into Chemotherapy, Targeted Therapy, and Immunotherapy. Based on Indication, the market is segmented into Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, and Others. Based on Dosage Form, the market is segmented into Solid, Liquid, Injectable, and Other. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Oncology Drugs Market

The rising global incidence of cancer is a major factor propelling the growth of the oncology drug market. Contributing factors include aging populations, changes in lifestyle, and environmental influences, all of which increase the overall burden of cancer. This heightened demand for effective treatments is consequently driving the need for oncology drugs. As the prevalence of cancer continues to rise, there is an urgent need for advanced and effective treatment options. The growing demand for oncology drugs reflects the necessity to address this expanding health challenge and provide effective solutions to manage and treat various types of cancer.

Restraints in the Global Oncology Drugs Market

One major restraint for the global oncology drugs market is the high cost associated with the development and treatment of cancer drugs. The extensive research, clinical trials, and regulatory approvals required for oncology drugs often result in significant expenses. These high costs can limit patient access to these treatments and pose financial challenges for healthcare systems and insurance providers. Additionally, the expense of cancer medications may hinder the market's growth, particularly in regions with limited healthcare budgets or in lower-income populations.

Market Trends of the Global Oncology Drugs Market

Targeted therapies have become a prominent trend in the development of oncology drugs. These treatments are engineered to precisely target cancer cells or their specific genetic mutations, thereby limiting harm to healthy cells. This focused approach has demonstrated significant potential in enhancing treatment outcomes and minimizing side effects. The advancement of targeted therapies represents a major shift in oncology, offering more effective and personalized treatment options. By concentrating on the unique characteristics of cancer cells, these therapies have shown promising improvements in patient outcomes and have contributed to a reduction in adverse effects commonly associated with traditional treatments.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Trade Analysis
Supply chain Analysis
Case study Analysis
Patent Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Oncology Drugs Market by Drug Class

Market Overview
Cytotoxic Drugs
- Alkylating Agents
- Antimetabolites
- Others
Targeted Drugs
- Monoclonal Antibodies
- Others
Hormonal Drugs
Others

Oncology Drugs Market by Therapy

Market Overview
Chemotherapy
Targeted Therapy
Immunotherapy

Oncology Drugs Market by Indication

Market Overview
Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Others

Oncology Drugs Market by Dosage Form

Market Overview
Solid
- Tablets
- Capsules
Liquid
Injectable
- Prefilled Syringes
- Others

Oncology Drugs Market by Distribution Channel

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Oncology Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals Incorporated (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seagen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Blueprint Medicines Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mirati Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Xencor, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Karyopharm Therapeutics Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exelixis, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments